Induction immunosuppression in solid organ transplantation involves a short course of potent immunosuppression in the perioperative period, with the goal of preventing early acute rejection and delaying initiation or reducing the dose of calcineurin inhibitors to minimize kidney injury. The use of induction immunosuppression in lung transplantation has increased over time, with over 80% of adult lung transplant recipients receiving some form of induction therapy. Currently, more than 70% of lung transplant recipients receive induction with an interleukin-2 receptor antagonist, and basiliximab is the most used agent. Despite this now common practice, the evidence to support and guide induction immunosuppression following lung transplantation is limited, making the use of induction somewhat controversial. Here, we review the available literature addressing the use of induction immunosuppression in lung transplant recipients.

中文翻译：

---

诱导治疗在肺移植中的作用


实体器官移植中的诱导免疫抑制涉及围手术期的短期强效免疫抑制，目的是防止早期急性排斥反应和延迟开始或减少钙调磷酸酶抑制剂的剂量，以尽量减少肾损伤。随着时间的推移，诱导免疫抑制在肺移植中的应用有所增加，超过 80% 的成年肺移植受者接受了某种形式的诱导治疗。目前，超过 70% 的肺移植受者接受白细胞介素 2 受体拮抗剂诱导，而巴利昔单抗是最常用的药物。尽管这种做法现在很普遍，但支持和指导肺移植后诱导免疫抑制的证据有限，这使得诱导的使用存在一些争议。在这里，我们回顾了关于在肺移植受者中使用诱导免疫抑制的现有文献。